12-0 vote in favor of GlaxoSmithKline's BCMA antibody coupling drug expected to be approved

Multiple myeloma is a malignant blood cancer caused by plasma cell cancer in myeloceutic sym? Abnormal growth ofplasma cells affects the production of normal blood cells, resulting in damage to the bones, immune system and kidneysAlthough there are a number of therapies that can be effective in treating multiple myeloma, tumor cells usually become resistant to existing treatments and recurtherefore, the development of innovative therapies is essentialBelantamab mafodotin is one of GSK's key research and development projectsit connects humanized anti-BCMA antibodies with cytotoxic agentsto kill cancer cells by targeting BCMA specifically into MM cellsBCMA is one of the most popular targets in recent years, it is a transmembrane glycoprotein, belonging to the tumor necrosis factor (TNF) receptor super family, also known as TNFRSF17 or CD269an important feature of this protein is its high expression on all MM cells, and it is not expressed in other normal tissues (except pulp cells), this target has become a popular target for many pharmaceutical companies and research institutions to develop treatments for patients with recurrent/refractive MMpreviously, belantamab mafodotin was approved by the FDA for breakthrough therapyBelantamab mafodotin is a key development of GSK's research therapy (Picture source: GSK official website) This recommendation is based on data from the DREAMM clinical trial project, including the key DREAMM-2 clinical study, which includes patients who have previously received a large number of treatments whose condition continues to deteriorate despite the current standard treatmentpreliminary results for six months of the study were published in The Lancet Oncology in December 2019 and serve as the basis for the BLADr Axel Hoos, Senior Vice President and Head of Oncology Research and Development at GSK, said, "We are pleased that the Committee recognizes the potential of belantamab mafodotin to help patients with recurrent/refractable multiple myeloma, an incurable disease with limited treatment optionswe look forward to working with the FDA to complete the review of our biological product seligible applications as soon as possible" References: GSK announces FDA advisory committee votes in favour of positive benefit/risk for profile belantamab mafodotin for patients with relapsed/turnmultiple myeloma Retrieved July 14, 2020, from the original title: Express , 12-0 vote by the Advisory Committee, GlaxoSmithKline BCMA Antibody Coupling Drug Expected to Be Approved